According to the new open source announcement, injectable human interleukin-2 developed by the company's shareholding company Beijing Liangyuan Biomedical Research Co., Ltd. has obtained implied approval for domestic clinical trials. The indication is advanced solid tumors. This product is original in China and the world's first novel drug for various solid tumors developed using a high-affinity hierarchical assembly technology platform. The company holds 23.8095% of Liangyuan Biotech's shares. This research and development progress is conducive to consolidating the company's pioneering position in the field of precision medicine and enhancing the company's core competitiveness.

Zhitongcaijing · 06/10 10:57
According to the new open source announcement, injectable human interleukin-2 developed by the company's shareholding company Beijing Liangyuan Biomedical Research Co., Ltd. has obtained implied approval for domestic clinical trials. The indication is advanced solid tumors. This product is original in China and the world's first novel drug for various solid tumors developed using a high-affinity hierarchical assembly technology platform. The company holds 23.8095% of Liangyuan Biotech's shares. This research and development progress is conducive to consolidating the company's pioneering position in the field of precision medicine and enhancing the company's core competitiveness.